跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03583099
NCT03583099已完成不适用

The CAPTURE Study: Validating a Unique Chronic Obstructive Pulmonary Disease (COPD) Case Finding Tool in Primary Care

Weill Medical College of Cornell University9 个研究点 分布在 1 个国家目标入组 2,004 人开始时间: 2018年10月12日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
2,004
试验地点
9
主要终点
Proportion of CAPTURE+ Participants Who Meet a Composite Endpoint for Diagnosis and Management of COPD
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A prospective, multicenter study including a cross-section validation to define sensitivity and specificity of CAPTURE to identify previously undiagnosed patients with clinically significant Chronic Obstructive Pulmonary Disease (COPD), and its impact on clinical care across a broad range of primary care settings in a cluster randomized controlled clinical trial.

详细描述

This is a large prospective, multi-center study explore the impact of the CAPTURE tool on clinical care and patient outcomes across a broad range of primary care settings in a cluster randomized controlled clinical trial.

The CAPTURE tool consists of a 5-item self-administered questionnaire and selected use of peak expiratory flow (PEF) measurement, designed to identify clinically significant COPD.

The CAPTURE study will enroll approximately 5,000 patients across 100 participating primary care clinics associated with practice-based research networks (PBRNs). Participants will be assessed with the CAPTURE Tool and have research spirometry testing.

Participating primary care practices will be randomized in a 1:1 fashion to one of the following interventions:

  • Arm 1: Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education (CAPTURE+ COPD education).
  • Arm 2: Practice clinicians will receive basic COPD education only (COPD education) and will be blinded to patient-level CAPTURE information.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Care Provider)

盲法说明

Practitioners at sites randomized to the COPD education only intervention will be blinded to CAPTURE scores.

Practitioners in both intervention arms will be blinded to research spirometry results.

Participants will be blinded to spirometry results.

入排标准

年龄范围
45 Years 至 80 Years（Adult, Older Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Provision of signed and dated informed consent form
  • •Stated willingness to comply with all study procedures and availability for the duration of the study
  • •Male or female, aged 45 - 80 years
  • •Able to read and speak English or Spanish

排除标准

  • •Previous clinician provided diagnosis of COPD
  • •Treated respiratory infection (with antibiotics and/or systemic steroids) in the past 30 days
  • •Participants unable to perform spirometry due to any of the following conditions within the past 30 days
  • •Chest surgery
  • •Abdominal surgery
  • •Eye surgery
  • •Heart attack

研究组 & 干预措施

COPD Education

Active Comparator

Practice clinicians will receive basic COPD education only.

干预措施: COPD Education Only (Other)

CAPTURE + COPD Education

Experimental

Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.

干预措施: COPD plus CAPTURE education and patient-level information (Other)

结局指标

主要结局

Proportion of CAPTURE+ Participants Who Meet a Composite Endpoint for Diagnosis and Management of COPD

时间窗: Baseline to 12 months

Proportion of CAPTURE+ participants who meet one of the following (composite endpoint): 1) referral for clinical spirometry testing, 2) new diagnosis of COPD, 3) newly prescribed respiratory medication (long acting bronchodilator or anti-inflammatory for respiratory condition), 4) referral to a specialist for respiratory evaluation/treatment, or 5) referral for or completion of pulmonary rehabilitation. CAPTURE+ is defined as Participants with: CAPTURE score ≥ 5, or CAPTURE score of 2, 3, or 4 with a low PEF, defined as \<350 L/min for males and \<250 L/min for females. CAPTURE scores range from 0 to 6. Higher values represent a higher likelihood of having clinically significant COPD.

次要结局

  • Proportion of CAPTURE+ Participants With Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Received Over-the-counter Patches/Gum for Smoking Cessation(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Who Are Referred for or Complete Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Who Are Newly Diagnosed With COPD(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Who Are Referred for or Complete Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Who Have Received a Recommendation for, or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Smoking at the Baseline With Any Components of the Primary Endpoint OR Any of the 4 Events Described in the Description Below.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Are Referred for or Complete Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Are Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral for, or Complete Pulmonary Rehabilitation.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive Clinician Counseling or Recommendation for Smoking Cessation(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Referral to a Smoking Cessation Program(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Capture Positive Participants Currently Smoking at Baseline Who Referral to a Smoking Quit Line(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Receive a Newly Prescribed Medication for Smoking Cessation.(Baseline to 12 months)
  • 12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Who Experience Exacerbations.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD With a Referral for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD With a Referral to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD With a New Diagnosis of COPD.(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD With Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Who Are Referred for or Complete Pulmonary Rehabilitation.(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Who Receive a Recommendation for or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Who Meet Any of the Components of the Primary Endpoint(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Mild COPD With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Mild COPD With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Referred for or Completion of Pulmonary Rehabilitation.(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Who Received a Recommendation or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred for or Completion of Clinical Spirometry Testing.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) With New Diagnosis of COPD.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Referred for or Completion of Pulmonary Rehabilitation.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Who Receive a Recommendation for or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred for or Completion of Clinical Spirometry Testing.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Referred for or Completion of Pulmonary Rehabilitation.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Who Receive a Recommendation or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Referred for or Complete Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Referred for or Complete Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Newly Diagnosed With COPD(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Newly Diagnosed With COPD(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 With Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 With Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Have Received a Recommendation for, or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Have Received a Recommendation for, or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Currently Smoking at Baseline Who Have Received a Recommendation for, or Administration of Influenza Vaccination(Baseline to 12 months)
  • 12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants Enrolled Before March 20, 2019(Baseline to 12 months)
  • 12-month Change in COPD Assessment Test (CAT) Score (12 Month CAT Change) in CAPTURE+ Participants Enrolled on or After March 20, 2019(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Exacerbations.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Experience Exacerbations.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 Who Meet Any of Components of the Primary Endpoints.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 Who Meet Any of Components of the Primary Endpoints.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 With a Referral for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled on or After March 20, 2019 With a Referral for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Enrolled After August 13, 2020 Who Receive a Recommendation for or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 With Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 With Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Are Referred for or Complete Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of Participants With Spirometric COPD Enrolled on or After March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of Mild COPD Participants Enrolled Before 3/20/2019 With Any of :1) Clinical Spirometry Referral, 2) New COPD Diagnosis, 3) Newly Prescribed Respiratory Medication, 4) Respiratory Specialist Referral, 5) Referral/Completion of Pulmonary Rehab(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 With a New Diagnosis of COPD (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled Before March 20, 2019 Who Received a Recommendation or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of Participants With Mild COPD Enrolled on or After March 20, 2019 Who Received a Recommendation or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of Participants With Preserved Ration, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ration, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 With New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 With New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 With a Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled Before March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Preserved Ratio, Impaired Spirometry (PRISm) Enrolled on or After March 20, 2019 Who Receive a Recommendation for or Administration of Influenza Vaccination(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Who Meet Any of the Components of the Primary Endpoint.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred for or Completion of Clinical Spirometry Testing(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 With a New Diagnosis of COPD (Abbreviated as Proportion in the Description)(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 With a New Diagnosis of COPD(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Newly Prescribed Respiratory Medication(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Referred to a Specialist for Respiratory Evaluation/Treatment(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Referred for or Completion of Pulmonary Rehabilitation(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled Before March 20, 2019 Who Receive a Recommendation or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of Participants With Symptomatic Non-obstructed (SNO) Enrolled on or After March 20, 2019 Who Receive a Recommendation or Administration of Influenza Vaccination.(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Who Experience Hospitalizations(Baseline to 12 months)
  • Number of Enrolled CAPTURE+ Participants Who Experience Mortality(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Hospitalizations(Baseline to 12 months)
  • Proportion of CAPTURE+ Participants Enrolled on or After March 20, 2019 Who Experience Hospitalizations(Baseline to 12 months)
  • Number of CAPTURE+ Participants Enrolled Before March 20, 2019 Who Experience Mortality.(Baseline to 12 months)
  • Number of CAPTURE+ Participants Enrolled After March 20, 2019 Who Experience Mortality.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD With a Referral for or Completion of Pulmonary Rehabilitation.(Baseline to 12 months)
  • Proportion of Participants With Clinically Significant COPD Who Receive a Recommendation for or Administration of Influenza Vaccination(Baseline to 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验

已完成
不适用
The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1)Chronic Obstructive Pulmonary Disease (COPD)
NCT03581227Weill Medical College of Cornell University4,679
已完成
不适用
The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 2)Chronic Obstructive Pulmonary Disease (COPD)
NCT03653611Weill Medical College of Cornell University196
已完成
不适用
Observational Study of Clinical Performance of a Sterile, Bacteria-binding, Super-absorbent Wound DressingWounds
NCT02662218BSN Medical GmbH32
进行中（未招募）
不适用
To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes MellitusDiabetes Mellitus, Type 2
NCT05926414Daewoong Pharmaceutical Co. LTD.15,000
已完成
不适用
Patient Reported Outcome Measures for Ablation of Cardiac ArrhythmiasCardiac Arrhythmia
NCT01672528Cardiff and Vale University Health Board586